FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder Meeting
Canada NewsWire TORONTO , April 5, 2021 /CNW/ – On Tuesday, March 30, 2021 , Anthony Durkacz , a
Read more
General
PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin
Canada NewsWire OXFORD, Ohio and COCONUT CREEK, Fla. , March 23, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB)
Read more
FACT, Inc. Announces Patricia Trompeter as CEO
Toronto, Ontario–(Newsfile Corp. – March 22, 2021) – FACT, Inc. (OTC Pink: FCTI) (the “Company” or “FACT“) a global leader
Read more
Harvest Health & Recreation Inc. To Hold Fourth Quarter and Full Year 2020 Earnings Conference Call
Harvest Health & Recreation Inc. To Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on March 30,
Read more
MINDCURE Announces Manufacturing of Synthetic Ibogaine to be Used in Company’s Clinical Research
Canada NewsWire The Company expects to have ibogaine manufactured and in use for research by Q4. VANCOUVER, BC , March
Read more
Glucose Health, Inc. – Amazon Revenues Exceed $50,000 Per Month
Bentonville, Arkansas–(Newsfile Corp. – March 1, 2021) – GLUCODOWN® (OTC Pink: GLUC) revenues at Amazon for the month of February 2021
Read more
Avance Clinical and Medidata Celebrate Strategic Partnership and Inhouse Expert Accreditation Milestones
ADELAIDE, AU, Feb 26, 2021 – (ACN Newswire) – The leading Australian CRO for biotechs, and Frost & Sullivan Asia-Pacific
Read more
Arbitrator Rules for Neptune Wellness Solutions Inc. in Dispute With Azpa Pharmaceuticals Pty. Ltd.
Canada NewsWire LAVAL, QC, Feb. 18, 2021/CNW/ –Neptune Wellness Solutions Inc.(“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX: NEPT), a diversified
Read more
Neptune Wellness Solutions Inc. Announces Termination of “At-The-Market” Offering
Canada NewsWire LAVAL, QC, Feb. 17, 2021/CNW Telbec/ – Neptune Wellness Solutions, Inc. (“Neptune” or the “Company”) (NASDAQ: NEPT) (TSX:
Read more
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for
Read more